Graseby Omnifuse PCA Syringe Pump, Recertified

Graseby Omnifuse PCA Syringe Pump, Recertified

Marsoni

M251S

$742.50

Get it in 3 business days with 1 day shipping. Friday, May 29

Graseby Omnifuse PCA Syringe Pump, RecertifiedDesigned with safety in mind, the Graseby (Smiths Medical) Omnifuse PCA breaks new ground in syringe pump design. Specifically developed for Patient Controlled Analgesia (PCA), Omnifuse PCA meets the needs of todays demanding pain management therapies. Specifications Dose Range: 0. 1ng 99. 9mg Duration: 1 second 15 minutes Clinician Override Dose Range: 0. 1ng 99. 9mg Loading Dose Range: 0. 1ng 99. 9mg Background Dose Rate Range: 0. 1ng h 500mg h

Easy Shipping

Quick Dispatch:

Your Graseby Omnifuse PCA Syringe Pump, Recertified orders ship within 1-2 business days.

Delivery Options:

Standard: 3-7 business days
Fast: 2-3 business days
Express: 1-2 business days

Order Tracking:

You'll receive a tracking link by email once your Graseby Omnifuse PCA Syringe Pump, Recertified ships.

Need Help?
Questions about Graseby Omnifuse PCA Syringe Pump, Recertified, sizing, or delivery? We're just an email away.

Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for Graseby Omnifuse PCA Syringe Pump, Recertified in your area.

Get Shipping Estimates

Country Zip/Postal Code

Exchange/Return Notes

We offer a 30-day return/exchange service after receiving.
Final sale items are not eligible for returns or exchanges.
To process your return/exchange, please contact us at [email protected]
Please click here for more details>>> Return & Exchange Policy

This suit is great! It is listed as a two piece suit, but it also comes with a tie and a lapel pin as seen on one of the pictures when you scroll down in the description. My son will be wearing it to prom with a different tie. Fits perfectly. He is 5 foot nine, around 155 pounds, and we ordered a size small. It literally looks tailored to him. Will post pictures after prom!

WAS THIS REVIEW HELPFUL?YesReportShare

Reviewed in the United States on April 20, 2026